| 摘要 |
This invention provides a compound of the formula (I): wherein A=B=D represents NR<SUP>10</SUP>-C(O)-NR<SUP>9</SUP>, S-C(O)-NR<SUP>9</SUP>, NR<SUP>9</SUP>-C(O)-S, NR<SUP>9</SUP>-C(O)-O, CR<SUP>10</SUP>-C(O)-NR<SUP>9</SUP>, O-C(O)-NR<SUP>9</SUP>, NR<SUP>10</SUP>-C(O)-CR<SUP>9</SUP>, NR<SUP>10</SUP>-NR<SUP>9</SUP>-C(O), C(O)-NR<SUP>9</SUP>-NR<SUP>10</SUP>, NR<SUP>10</SUP>-N-CR<SUP>9</SUP>, N-N-CR<SUP>9</SUP>, NR<SUP>10</SUP>-CR<SUP>9</SUP>-N, N-CR<SUP>9</SUP>-NR<SUP>10</SUP>, NR<SUP>10</SUP>-N-N, N-N-NR<SUP>10</SUP>, S-CR<SUP>9</SUP>-N or N-CR<SUP>9</SUP>-S; X<SUP>1 </SUP>represents CR<SUP>1 </SUP>or N; X<SUP>2 </SUP>and X<SUP>3 </SUP>each independently represents CR<SUP>8 </SUP>or N; R<SUP>1</SUP>, R<SUP>6</SUP>, R<SUP>8</SUP>, R<SUP>9 </SUP>and R<SUP>10 </SUP>each independently represents hydrogen, halogen, hydroxy, (C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl, (C<SUB>1</SUB>-C<SUB>6</SUB>)alkoxy, hydroxy(C<SUB>1</SUB>-C<SUB>6</SUB>)alkoxy, (C<SUB>1</SUB>-C<SUB>6</SUB>)alkoxy-(C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl, (C<SUB>1</SUB>-C<SUB>6</SUB>)alkoxy-(C<SUB>1</SUB>-C<SUB>6</SUB>)alkoxy, halo(C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl, (C<SUB>1</SUB>-C<SUB>6</SUB>)alkylthio, (C<SUB>1</SUB>-C<SUB>6</SUB>)alkylsulfinyl or (C<SUB>1</SUB>-C<SUB>6</SUB>)alkylsulfonyl; R<SUP>2</SUP>, R<SUP>3</SUP>, R<SUP>4</SUP>, and R<SUP>5 </SUP>each independently represents hydrogen, (C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl, halogen, halo(C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl, or hydroxy(C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl; and R<SUP>7 </SUP>represents halogen, (C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl, halo(C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl, (C<SUB>1</SUB>-C<SUB>6</SUB>)alkoxy, hydroxy(C<SUB>1</SUB>-C<SUB>6</SUB>)alkoxy, (C<SUB>1</SUB>-C<SUB>6</SUB>)alkoxy-(C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl, (C<SUB>1</SUB>-C<SUB>6</SUB>)alkoxy-(C<SUB>1</SUB>-C<SUB>6</SUB>)alkoxy, [(C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl]NH- or [(C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl]<SUB>2</SUB>N-; or a pharmaceutically acceptable salt thereof, provided that: (i) when A=B=D represents NR<SUP>10</SUP>-N-N or N-N-NR<SUP>10</SUP>, then R<SUP>2 </SUP>represents (C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl, halogen, halo(C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl or hydroxy(C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl; or (ii) when A=B=D represents NR<SUP>10</SUP>-N-N or N-N-NR<SUP>10</SUP>, and R<SUP>2 </SUP>represents (C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl, then R<SUP>7 </SUP>represents halogen, (C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl, (C<SUB>1</SUB>-C<SUB>6</SUB>)alkoxy, hydroxy(C<SUB>1</SUB>-C<SUB>6</SUB>)alkoxy, (C<SUB>1</SUB>-C<SUB>6</SUB>)alkoxy-(C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl, (C<SUB>1</SUB>-C<SUB>6</SUB>)alkoxy-(C<SUB>1</SUB>-C<SUB>6</SUB>)alkoxy, [(C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl]NH- or [(C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl]<SUB>2</SUB>N-. These compounds are useful for the treatment of disease conditions caused by overactivation of VR1 receptor such of pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.
|
